resiquimod has been researched along with Pancreatic Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Belt, BA; Garrett-Larsen, J; Gerber, SA; Han, BJ; Johnston, CJ; Linehan, DC; Lord, EM; Mills, BN; Murphy, JD; Qin, SS; Uccello, TP; Vrooman, TG; Ye, J | 1 |
| Angeles Ramos, DM; Burfeind, KG; Coussens, LM; Levasseur, PR; Liudahl, SM; Marks, DL; Maurer, HC; Michaelis, KA; Morgan, TK; Norgard, MA; Olive, KP; Olson, B; Pelz, KR; Sivagnanam, S; Zhu, X | 1 |
| Caisova, V; Chlastakova, A; Chmelar, J; Frejlachova, A; Hansen, P; Kopecky, J; Kvardova, K; Lencova, R; Masakova, K; Pacak, K; Padoukova, L; Skalickova, M; Uher, O; Venhauerova, A; Zenka, J; Zhuang, Z | 1 |
| Caisová, V; Chmelař, J; Jochmanová, I; Kopecký, J; Krejčová, G; Kvardová, K; Masáková, K; Nedbalová, P; Paďouková, L; Uher, O; Ženka, J | 1 |
| Hobohm, U; Linnebacher, M; Maletzki, C; Savai, R | 1 |
| Blaheta, RA; Chandraker, A; Friess, H; Gasser, M; Germer, CT; Grimm, M; Grimmig, T; Hoeland, K; Matthes, N; Moench, R; Moll, EM; Tripathi, S; Tsaur, I; Waaga-Gasser, AM | 1 |
6 other study(ies) available for resiquimod and Pancreatic Neoplasms
| Article | Year |
|---|---|
Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
Topics: Adjuvants, Immunologic; Animals; Antigens, Neoplasm; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Disease Models, Animal; Humans; Imidazoles; Liver Neoplasms; Mice; Pancreatic Neoplasms; Radiosurgery; Toll-Like Receptor 7; Toll-Like Receptor 8; Tumor Microenvironment | 2022 |
The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer.
Topics: Animals; Body Weight; Cachexia; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Eating; Gene Expression; Humans; Imidazoles; Locomotion; Mice; Mice, Knockout; Pancreatic Intraductal Neoplasms; Pancreatic Neoplasms; Sequence Analysis, RNA; Survival Rate; Toll-Like Receptor 7; Toll-Like Receptor 8; Tumor Burden; Tumor Microenvironment | 2019 |
Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; CD40 Antigens; Imidazoles; Immunotherapy; Ligands; Lipopolysaccharides; Mannans; Mice; Pancreatic Neoplasms; Poly I-C; T-Lymphocytes; Teichoic Acids; Toll-Like Receptors | 2021 |
Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Female; Imidazoles; Immunotherapy; Lipopolysaccharides; Lymphocytes, Tumor-Infiltrating; Mannans; Melanoma, Experimental; Mice, Inbred C57BL; Neutrophils; Pancreatic Neoplasms; Phagocytosis; Poly I-C; Teichoic Acids; Toll-Like Receptors; Tumor Burden | 2018 |
Mistletoe lectin has a shiga toxin-like structure and should be combined with other Toll-like receptor ligands in cancer therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Flagellin; Humans; Imidazoles; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Mistletoe; Models, Molecular; Neoplasms, Experimental; Pancreatic Neoplasms; Phytotherapy; Plant Lectins; Protein Conformation; Shiga Toxin; Time Factors; Toll-Like Receptors; Treatment Outcome; Tumor Burden | 2013 |
TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer.
Topics: Aged; Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Mice; Middle Aged; Neoplasm Transplantation; Pancreatic Neoplasms; Retrospective Studies; Toll-Like Receptor 7; Toll-Like Receptor 8 | 2015 |